Eventuelle komplikationer kan ofte undgås ved at sørge for, − at patienterne ikke er overfølsomme for normalt humant immunoglobulin ved først at infusere produktet langsomt (0, 01 ml/ kg kropsvægt/ min); − at patienterne overvåges omhyggeligt for symptomer gennem hele infusionsperioden.
Potential complications can often be avoided by ensuring − that patients are not sensitive to human normal immunoglobulin by first infusing the product slowly (0.01 ml/kg BW/min); − that patients are carefully monitored for any symptoms throughout the infusion period.